Latest Health News

Tasmea Limited has declared a fully franked special dividend of 12 cents per share, reflecting robust financial performance and strong confidence in future growth prospects.

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.

Pepper Money Limited has announced a fully franked special dividend of 12.5 cents per share, reflecting its robust cash position and ongoing capital management strategy. The payout totals approximately $55.5 million, with key dates set for June and July 2025.

INOVIQ Limited has revealed promising data for its EXO-OC™ ovarian cancer screening test, demonstrating exceptional accuracy and flawless detection of early-stage cancers. This innovation could transform early diagnosis and treatment outcomes for women worldwide.

Cardiex Limited has gained Therapeutic Goods Administration approval for its CONNEQT Pulse device, paving the way for commercial expansion in Australia alongside its established US presence.

Bio-Gene Technology Limited has raised $338,500 through a Share Purchase Plan, contributing to a total capital raise of $2.45 million to advance its bio-insecticide products.

HITIQ has secured a pivotal one-year deal with the South Metro Junior Football League, positioning its PROTEQT concussion management system at the heart of junior sports safety. This move complements existing partnerships and signals a strong push into Australia’s grassroots sports market.

Hydralyte USA reports its best EBITDA performance since IPO, driven by strong sales and cost reductions, setting the stage for growth with upcoming product launches.

EVE Health Group has initiated stability testing for its novel oral treatments targeting erectile dysfunction and dysmenorrhea, marking a crucial step toward regulatory approval in Australia. The company also finalizes its acquisition of Nextract, the developer behind these innovative formulations.

Resimac Group Limited has announced a fully franked special dividend of 12 cents per share following a strategic review and sale of non-core assets, signalling disciplined capital management and shareholder value focus.

Opthea Limited faces a pivotal moment as four board members resign following disappointing Phase 3 trial results and a major workforce reduction. The company’s future hinges on ongoing funding negotiations amid trading suspensions.

Singular Health Group has completed a $773,000 placement with Marin and Sons, alongside exercising options and issuing shares under its employee incentive plan, strengthening its capital base.